111 related articles for article (PubMed ID: 26260873)
21. Combined taxane-based chemotherapy and intensity-modulated radiotherapy with simultaneous integrated boost for gastroesophageal junction adenocarcinoma.
Spatola C; Tocco A; Pagana A; Milazzotto R; Luigi R; Salamone V; Militello C; Migliore M; Foti PV; Cataldo AD; Acquaviva G; Privitera G
Future Oncol; 2018 Mar; 14(6s):47-51. PubMed ID: 29664354
[TBL] [Abstract][Full Text] [Related]
22. A case of complete response to S-1 plus CDDP in early-stage mucosal esophageal cancer.
Takayama Y; Kochi M; Fujii M; Kanamori N; Kaiga T; Mihara Y; Miyazaki T; Tamegai H; Watanabe M; Takayama T
Anticancer Res; 2011 Mar; 31(3):1019-22. PubMed ID: 21498731
[TBL] [Abstract][Full Text] [Related]
23. [A case of adenocarcinoma of the esophagogastric junction successfully treated with chemoradiation therapy].
Ebisui C; Okada K; Nishigaki T; Owada Y; Nagase H; Mukai R; Momozane T; Murakami M; Ide Y; Yanagisawa T; Murata K; Yokouchi H; Tamai M; Kinuta M
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2143-5. PubMed ID: 22202310
[TBL] [Abstract][Full Text] [Related]
24. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
Shah MA; Ramanathan RK; Ilson DH; Levnor A; D'Adamo D; O'Reilly E; Tse A; Trocola R; Schwartz L; Capanu M; Schwartz GK; Kelsen DP
J Clin Oncol; 2006 Nov; 24(33):5201-6. PubMed ID: 17114652
[TBL] [Abstract][Full Text] [Related]
25. Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma.
Blom RL; Sosef MN; Nap M; Lammering G; van den Berkmortel F; Hulshof MC; Meijer SL; Wilmink HW; van Berge Henegouwen MI
Dis Esophagus; 2014; 27(4):380-7. PubMed ID: 24006852
[TBL] [Abstract][Full Text] [Related]
26. [Biochemical modulation of 5-FU--effect of low dose CDDP].
Hirata K; Yamamitsu S; Tsuji A; Shirasaka T; Mukaiya M; Oikawa I; Kimura H; Sasaki K; Denno R
Gan To Kagaku Ryoho; 1999 Mar; 26(4):467-75. PubMed ID: 10097743
[TBL] [Abstract][Full Text] [Related]
27. Multicenter Phase 2 Study of Peri-Irradiation Chemotherapy Plus Intensity Modulated Radiation Therapy With Concurrent Weekly Docetaxel for Inoperable or Medically Unresectable Nonmetastatic Gastric Cancer.
Liu Y; Zhao G; Xu Y; He X; Li X; Chen H; Wu Q; Yao S; Yan G; Chen T
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1096-1105. PubMed ID: 28721893
[TBL] [Abstract][Full Text] [Related]
28. Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes.
McNamara MJ; Adelstein DJ; Allende DS; Bodmann JW; Ives DI; Murthy SC; Raymond D; Raja S; Rodriguez CP; Sohal D; Stephans KL; Videtic GMM; Rybicki LA
J Gastrointest Cancer; 2017 Jun; 48(2):181-189. PubMed ID: 27734205
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma.
Xia Y; Li YH; Chen Y; Zhang JH; Liu Q; Deng JY; Ai TS; Zhu HT; Fan JH; Badakhshi H; Zhao KL
Radiat Oncol; 2017 Mar; 12(1):47. PubMed ID: 28270162
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Loupakis F; Masi G; Fornaro L; Vasile E; Allegrini G; Fontana E; Granetto C; Salvatore L; Mentuccia L; Andreuccetti M; Cortesi E; Merlano M; Cascinu S; Falcone A
Cancer Chemother Pharmacol; 2010 Aug; 66(3):559-66. PubMed ID: 20237927
[TBL] [Abstract][Full Text] [Related]
32. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
Bascoul-Mollevi C; Gourgou S; Galais MP; Raoul JL; Bouché O; Douillard JY; Adenis A; Etienne PL; Juzyna B; Bedenne L; Conroy T
Eur J Cancer; 2017 Oct; 84():239-249. PubMed ID: 28829992
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.
Ajani JA; Mansfield PF; Crane CH; Wu TT; Lunagomez S; Lynch PM; Janjan N; Feig B; Faust J; Yao JC; Nivers R; Morris J; Pisters PW
J Clin Oncol; 2005 Feb; 23(6):1237-44. PubMed ID: 15718321
[TBL] [Abstract][Full Text] [Related]
34. Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer.
Thukral A; Metz J; Hwang WT; O'Dwyer P; Plastaras J; Both S; Bar-Ad V
Dis Esophagus; 2011 Jul; 24(5):330-6. PubMed ID: 21143694
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
Watanabe M; Baba Y; Yoshida N; Ishimoto T; Nagai Y; Iwatsuki M; Iwagami S; Baba H
Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
[TBL] [Abstract][Full Text] [Related]
36. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Park JW; Kim JH; Choi EK; Lee SW; Yoon SM; Song SY; Lee YS; Kim SB; Park SI; Ahn SD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):691-7. PubMed ID: 20888705
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
[TBL] [Abstract][Full Text] [Related]
39. [Esophageal cancer: outcome according to therapeutic strategy].
Rousseau D; Capitain O; Denis F; Girault S; Poirier AL; Paumier A; Cellier P; Hamy A; Mahé MA; Mesgouez-Nebout N
Cancer Radiother; 2013 Feb; 17(1):10-20. PubMed ID: 23270680
[TBL] [Abstract][Full Text] [Related]
40. Nonsurgical management of esophageal adenocarcinoma.
Gujral DM; Hawkins MA; Leonulli BG; Ashley S; Chau I; Cunningham D; Tait D
Clin Colorectal Cancer; 2011 Sep; 10(3):165-70. PubMed ID: 21855037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
